Brian Skorney

Graig Suvannavejh × Sam Fazeli × Eric Schmidt × Brian Skorney

Biotech’s 27% XBI gain through September masks a punishing ownership unwind, as underowned and heavily shorted names offset specialist-fund selling.Regeneron-Sanofi’s $1 billion upfront and AstraZeneca’s $2 billion Summit investment show strategic capital is flowing, but HARMONi-3 remains a potentially historic binary event.China-origin deals and Lilly’s obesity data sharpen competition, while financing, durability, tolerability, and endpoint risk still dictate outcomes.

Sam Fazeli × Yaron Werber × Brian Skorney × Matt Gline

Biotech’s healthy headline tape masked long-short degrossing and rate sensitivity, while 22 IPOs and record-period average proceeds showed primary-market resilience.MFN may rebalance global contributions through revenue sharing rather than simply cut U.S. prices, but Europe could restrict access or favor cheaper Chinese drugs; meanwhile, durable VK2735 efficacy, Celldex safety and Vertex’s interim analysis define catalysts.

Tess Cameron × Brian Skorney × Paul Matteis × Yaron Werber

HORIZON was “completely negative” despite pelacarsen reducing Lp(a) 80%, challenging biomarker shortcuts as Amgen fell 10% on read-through.Novartis’s Avidity failure less than a year after the $12 billion acquisition drove Artisan’s sales cut of about $5 billion and EPS CAGR to 4%.Dyne’s 25% placebo-adjusted CASI-22 splice correction and Roivant’s 56% PVR reduction set up catalysts, while endpoint and outcome risks remain.

Sam Fazeli × Brian Skorney × Yaron Werber × Jake Becraft

Biotech’s washout is intensifying: 16 of 18 2024 IPOs trade below issue at a median 61% decline, despite Jake Becraft seeing fundamentals intact.Weak commercialization economics reinforce M&A dependence; Pfizer’s planned BD activity and obesity interest, plus Jazz-Chimerix and AbbVie-Gubra, point to catalysts while Pliant and Biohaven test differentiation.

Graig Suvannavejh × Tim Opler × Yaron Werber × Paul Matteis × Brian Skorney

Biotech is decisively outperforming, with XBI +24% YTD versus +9% for the S&P 500, as Graig sees FDA headwinds turning into tailwinds alongside 14 IPOs and $300B+ of pharma revenue at LOE risk.Reverse mergers now rival traditional IPOs, while J&J’s $785M Sail deal and $2.6B acquisition option reinforce hot in vivo CAR-T M&A.Alnylam’s roughly 30% TTR sell-off and Novo’s ZEUS miss leave upcoming data and year-end M&A as key tests.

Josh Schimmer × Brian Skorney × Eric Schmidt × Brad Loncar

Scribe’s IPO raised roughly $120M for a TGA-cleared PCSK9 gene-silencing therapy, reopening the very-early-stage biotech window.Six biotech reverse mergers paired with $200M-plus PIPEs, including Xometry’s nearly $200M transaction into InMed, show a faster, increasingly IPO-like financing route.Next week’s RP1 and deramiocel AdComs could clarify whether FDA flexibility is emerging or negative findings signal a more stringent posture.

Yaron Werber × Tess Cameron × SamFazeli × Brian Skorney

AI is driving biotech’s tape: SMH is up 66% year-to-date versus IBB at 1% and XBI at 8%, while BIOSECURE and expanded COINS-style screening could redirect China dealmaking toward Europe.Ivonescimab cut death risk 34% in HARMONi-6, while daraxonrasib extended survival to 13.2 versus 6.7 months; SERENA-4 and CDK4 readouts, translatability, toxicity, and in vivo CAR-T durability warrant monitoring.

Sam Fazeli × Paul Matteis × Brian Skorney × Tess Cameron

Biotech enters JPM week with XBI at 125.53, as specialist-backed companies with fundamental progress—not indiscriminate buying—drove 2025 returns.Merck’s rumored $28–32bn Revolution Medicines bid could bring cash into the sector despite a rich EV/sales multiple, while Aktis’s $318m data-free IPO shows financing appetite; CMS MFN policy, anti-drug-antibody diligence, and upcoming clinical data remain risks.

Daphne Zohar × Bruce Booth × Sam Fazeli × Brian Skorney × Yaron Werber × Eric Schmidt

Biotech's rebound is broadening as sub-cash companies fall from 200+ to 50 and M&A approaches its strongest year since 2019.Bruce sees IPOs reopening in early 2026, but $40-50M in first-two-year costs favor private financing.Avidity's $12B pre-Phase 3 sale, Catalent's CMC failures, and Intellia's day-30 toxicity keep platform durability, manufacturing, and safety in focus.

Chris Garabedian × Brian Skorney × Sam Fazeli

Biotech’s catch-up trade is gaining traction as healthcare ranks among the month’s most net-bought sectors and exposure approaches five-year highs without “crazy valuations.”Financings are shifting from dilution overhang to FOMO, with Alto Neuroscience up 65% around a $50M PIPE and Nurix’s $250M registered direct, while ivonescimab’s PFS win leaves OS and the VEGF contribution unresolved.